- Home
- AMST vs MYNZ Comparison
AMST vs MYNZ Comparison
Compare AMST & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AMST | MYNZ |
|---|---|---|
| Founded | 2017 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.8M | 10.6M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMST | MYNZ |
|---|---|---|
| Price | $2.11 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $14.00 |
| AVG Volume (30 Days) | ★ 508.1K | 454.1K |
| Earning Date | 02-09-2026 | 09-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $193,505.00 | ★ $659,935.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 68.56 | N/A |
| 52 Week Low | $1.79 | $0.92 |
| 52 Week High | $4.78 | $8.20 |
Technical Indicators
Market Signals| Indicator | AMST | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 48.94 |
| Support Level | $1.87 | $1.12 |
| Resistance Level | $2.15 | $1.20 |
| Average True Range (ATR) | 0.13 | 0.12 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 72.22 | 21.10 |
Price Performance
Historical ComparisonAbout AMST Amesite Inc.
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.